Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP2201 vs Co-administered RLD2205 and RLD2206 in Healthy Males
NCT05737082Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP-2201 in prostate cancer (PCa) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Abiraterone acetate Area Under the Curve to the last measurable concentration, Abiraterone acetate Maximum Plasma Concentration and 2 more. Started Mar 2023; status: completed.
02
Drugs
HCP-2201
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05737082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737082.